Monday, 13 February 2017
Ann Arbor, Michigan, USA/Feb 13, 2017
A new technology that predicts an individual’s risk for developing cardiovascular disease has been launched today by Everist Health Inc of Ann Arbor, Michigan. “Eighteen million people die every year from cardiovascular disease,“ says Everist Health CEO Matt Bartlam. “It is the world’s number one killer. I believe our test can make a major contribution to improving the world’s cardiovascular health for several reasons.
“First, the test is non-invasive, painless and produces results in under twenty minutes. The results provide medical professionals with important new data on one’s current cardiovascular health that, at the same time, is translated into simple numbers that we can all use and understand
“The new test uses elements of pulse wave analysis and plesmography to measure the flexibility of a person’s arteries which is recognized as a very good predictor of future risk. A device, known as AngioDefender™, measures the percentage flow mediated dilation (FMD) of a patient’s arteries- the ability of arteries to contract and expand. This reading, together with other basic patient details such as: age, blood glucose levels and cholesterol levels can then be used to quickly calculate a person’s heart and cardiovascular age.
“So, while the medical professional gets new and very important medical data -the FMD score, the individual can have their medical assessment translated into a simple heart age number that is easy to understand and relate to. If an individual’s heart age turns out to be lower than their actual age the message is to continue doing the things that are contributing to a healthy cardiovascular system such as diet, exercise and non-smoking – but if the heart age is higher than a person’s chronological age, this can be a powerful driver of behavior change to lower the risk of a heart attack or stroke.
“Although there are other ways of estimating an individual heart age, it is important to recognize that our method permits a personal calculation based on the individual’s actual medical information rather than on general historical population data,” says Matt Bartlam.
Importantly, the AngioDefender™ test can reveal cardiovascular problems in people that may appear to be at low risk such as athletes or young apparently fit, non- smokers with a healthy lifestyle. So called asymptomatic people.
Everist Health believes that this new test can have wide applications because it is light, mobile and does not require a specially trained operator. “It can be made available to the public in a variety of non- hospital environments . We have conducted many successful tests in Canada, Europe and India and it has been shown to work well in several different markets. For example, the health testing of transport workers in their workplace in Mumbai, India, and corporate wellness program, community care facilities and rehabilitation centres in Canada.
“At the same time researchers in the UK National Health Service are using the technology in trials where new cancer drugs are being monitored for potential cardiovascular side effects.
“Eventually I believe our technology will find wide application globally, including in countries where the hospital systems are poorly developed,” says Matt Bartlam who points out that interest has been shown by health workers in Africa.
Initially the new technology will be available in Germany, the UK, Canada and India where multiple trials are ongoing and distributors are in place. The company has immediate plans to broaden availability to Austria, Switzerland, Australia and, by 2018, the entire European Union. The technology has also been the subject of trials in the USA which have recently been concluded. “We expect to submit our findings to the FDA in the next few months,” says Matt Bartlam.
Monday, 05 October 2015
Published October 5, 2015
One of Europe's leading research centers, Charité Medical University in Berlin, is using a new device called AngioDefender to investigate a condition that is commonly called "broken heart syndrome". The disease has been given its name because it tends to occur in patients that have suffered severe emotional stress such as the death of a loved one. One of the mysteries surrounding the disease is that 90 percent of patients are women over 58.
Sufferers appear to be having a heart attack, but in fact they are suffering a sudden temporary weakening of the muscle walls of the heart which results in the heart changing shape.
Takotsubo cardiomyopathy- to give the disease its proper name- was not identified until the 1990s by Japanese researchers. They named Takotsubo after the elongated shape of the heart which is similar to the shape of octopus traps used by the countries fisherman.
Researchers speculate that hormonal changes may play a role and risk factors appear to include neurological and psychiatric disorders, although, data remains scarce.
Researchers are aware, however, that the endothelial cells that line every artery of the body play an important role in cardiovascular health. The scientist in charge of the German clinical trial, Dr. Ute Seeland, will be using the device known as AngioDefender, to help unravel one of the mysteries that surround the disease.
AngioDefender takes a series of measurements including a subject's blood pressure, pulse rate and importantly the ability of a subjects arteries to expand and contract to permit blood to flow as needed. In less than 20 minutes, information is produced by AngioDefender which is used to calculate the health of the single layer of endothelial cells lining the vascular system. If these cells are damaged, it might be due to severe stress or a subject's lifestyle, which in turn might suggest a possible treatment.
"It is very encouraging to know that our technology can be used by the world renowned Charité Research Centre to investigate a life threatening condition on which little is currently known," says Matt Bartlam the CEO of Everist Health, the developers of AngioDefender. "Our technology is non- invasive, low cost, simple to use and provides an immediate result which we believe will help researchers at Charité and around the world investigate many aspects of cardiovascular disease."
"Heart disease remains the number one killer in the world and is responsible for more deaths than all types of cancer combined," says Mr. Bartlam. "So, in addition to solving the mysteries of Takotsubo cardiomyopathy, we have to step up our research efforts to avoid breaking millions more hearts."
Notes for editors:
For more information on research into Takotsubo cardiomyopathy, contact Mrs. Dr. med.Ute Seeland (M. D.) at Charité - Universitätsmedizin Berlin, Berlin at Hessische Str. 3-4, D-10115 Berlin.
About Charité research:
There are over 4,500 scientists at the Charité Medical Faculty engaged in frontier biomedical research .
In 2014, the Faculty raised more than 151 million Euros from public and private investors to finance its research activities. This enabled it to secure a top position among the medical faculties in Germany and become the leader in Europe.
Monday, 23 June 2014
GoPathDx's Ongoing Lecture Series Announcement! "How Molecular Diagnostics Affects the Management of Early Stage CRC"
Presenter:Peter Lenehan, MD PhD
Friday, 13 September 2013
Date: Saturday, June 28th, 2014
A new approach to solving heart disease will be demonstrated to hundreds of physicians and cardiologists at a conference in Bangalore next month.
Thursday, 20 June 2013
A new, simple, non-invasive test that predicts risk for cardiovascular disease is to be made available by Gulf & Word Traders throughout the United Arab Emirates and neighboring countries
June 20, 2013 - Everist Health Inc. (Ann Arbor, MI) developer of the test, announced today that they have appointed Gulf & World Traders as exclusive agents of the technology in the region.
Tuesday, 12 March 2013
Ann Arbor, Michigan, USA, March 12, 2013. A new test that detects asymptomatic individuals who may be at risk for cardiovascular disease is being launched in Europe at the Healthcare Innovation Expo 2013. The device, known as AngioDefender, was developed by Everist Health, Inc. of Ann Arbor, Michigan, USA, in collaboration with scientists at Rutgers University, New Jersey. The developers claim that the test will lower the cost of detecting and treating cardiovascular problems and improve patient outcomes.
Wednesday, 28 November 2012
Rutgers and Everist Health work to detect early-stage disease in asymptomatic patients
Rutgers announced today that it has agreed to an exclusive license with Everist Health Inc. for the patents covering a novel technology that enables the early measurement of various vascular conditions. Gary M. Drzewiecki, professor in the university’s Department of Biomedical Engineering, developed the technology.